Enliven Therapeutics, Inc. (ELVN)
ELVN has a market cap or net worth of $886.02 million. The enterprise value is $593.87 million.
The next estimated earnings date is Wednesday, August 2, 2023, before market open.
|Earnings Date||Aug 2, 2023|
ELVN has 41.11 million shares outstanding. The number of shares has increased by 543.59% in one year.
|Shares Change (YoY)||+543.59%|
|Shares Change (QoQ)||+177.58%|
|Owned by Insiders (%)||n/a|
|Owned by Institutions (%)||n/a|
The trailing PE ratio is 13.14.
|EV / Earnings||423.28|
|EV / Sales||n/a|
|EV / EBITDA||278.42|
|EV / EBIT||398.30|
|EV / FCF||n/a|
The company has a current ratio of 27.24
|Debt / Equity||n/a|
|Debt / EBITDA||n/a|
|Debt / FCF||n/a|
Return on equity (ROE) is 1.10% and return on invested capital (ROIC) is 14.60%.
|Return on Equity (ROE)||1.10%|
|Return on Assets (ROA)||1.10%|
|Return on Capital (ROIC)||14.60%|
|Revenue Per Employee||n/a|
|Profits Per Employee||n/a|
In the past 12 months, ELVN has paid $88,000 in taxes.
|Effective Tax Rate||5.90%|
Stock Price Statistics
The stock price has increased by +374.29% in the last 52 weeks.
|52-Week Price Change||+374.29%|
|50-Day Moving Average||20.26|
|200-Day Moving Average||16.65|
|Average Volume (30 Days)||132,869|
Short Selling Information
|Short Previous Month||n/a|
|Short % of Shares Out||n/a|
|Short % of Float||n/a|
|Short Ratio (days to cover)||n/a|
|Earnings Per Share (EPS)||$1.64|
|Cash & Cash Equivalents||292.16M|
|Net Cash Per Share||$7.11|
|Equity / Book Value||291.42M|
|Book Value Per Share||7.09|
In the last 12 months, operating cash flow was -$39.25 million and capital expenditures -$259,000, giving a free cash flow of -$39.51 million.
|Operating Cash Flow||-39.25M|
|Free Cash Flow||-39.51M|
|FCF Per Share||-$2.13|
Dividends & Yields
ELVN does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for ELVN is $27.00, which is 25.29% higher than the current price. The consensus rating is "Strong Buy".
|Price Target Difference||25.29%|
|Analyst Consensus||Strong Buy|
|Revenue Growth Forecast (5Y)||n/a|
|EPS Growth Forecast (5Y)||n/a|
This stock does not have any record of stock splits.
|Last Split Date||n/a|